| Literature DB >> 32110401 |
John Bonnewell1, Sarah Magaziner2, Joseph L Fava3, Madeline C Montgomery4, Alexi Almonte5, Michael Carey3, Philip A Chan4,5.
Abstract
BACKGROUND: In the United States, syphilis cases have increased dramatically over the last decade. Recognition and timely diagnosis by medical providers are essential to treating syphilis and preventing further transmission.Entities:
Keywords: Syphilis; diagnosis; healthcare providers; medical students; prevention
Year: 2020 PMID: 32110401 PMCID: PMC7000862 DOI: 10.1177/2050312120902591
Source DB: PubMed Journal: SAGE Open Med ISSN: 2050-3121
Demographics and clinical experience of survey participants.
| Total (%) | Medical students (%) | Residents/fellows (%) | Non-ID attendings (%) | ID attendings (%) | |
|---|---|---|---|---|---|
| ( | ( | ( | ( | ( | |
| Sex | |||||
| Male | 41.5 | 31.7 | 45.6 | 51.8 | 61.9 |
| Female | 51.0 | 58.7 | 49.4 | 48.2 | 33.3 |
| No response | 6.5 | 9.6 | 5.1 | 0.0 | 4.7 |
| Age | |||||
| <25 years | 20.3 | 45.2 | 0.0 | 0.0 | 0.0 |
| 25–34 years | 59.7 | 53.9 | 96.2 | 11.1 | 14.3 |
| 35–44 years | 6.1 | 1.0 | 3.8 | 25.9 | 14.3 |
| 45–54 years | 6.5 | 0.0 | 0.0 | 29.6 | 33.3 |
| 55–64 years | 6.1 | 0.0 | 0.0 | 29.6 | 28.6 |
| 65+ years | 1.3 | 0.0 | 0.0 | 3.7 | 9.5 |
| Race | |||||
| American Indian/Native American | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Asian/Pacific Islander | 22.9 | 30.8 | 20.3 | 14.8 | 4.8 |
| Black/African American | 7.8 | 10.6 | 8.9 | 0.0 | 0.0 |
| White | 61.9 | 49.0 | 64.6 | 81.5 | 90.5 |
| Multiracial/other/unknown | 7.4 | 9.6 | 6.3 | 3.7 | 4.8 |
| Ethnicity | |||||
| Non-Hispanic/Latino | 65.4 | 65.4 | 63.3 | 70.4 | 52.4 |
| Hispanic/Latino | 9.5 | 14.4 | 6.3 | 3.7 | 4.8 |
| No response | 25.1 | 20.2 | 26.6 | 25.9 | 42.9 |
| Number of patients screened for syphilis (last 12 months) | |||||
| None | 40.3 | 73.1 | 8.9 | 29.6 | 9.5 |
| 1–10 | 31.6 | 16.4 | 48.1 | 40.7 | 33.3 |
| 10–20 | 17.8 | 7.7 | 30.4 | 25.9 | 9.5 |
| 30–50 | 5.2 | 2.9 | 7.6 | 0.0 | 14.3 |
| 50–100 | 3.5 | 0.0 | 5.6 | 0.4 | 14.3 |
| >100 | 1.7 | 0.0 | 0.0 | 0.0 | 19.5 |
| Number of patients treated or referred for treatment for syphilis (last 12 months) | |||||
| None | 70.6 | 85.6 | 67.1 | 59.2 | 23.9 |
| 1 | 16.0 | 11.5 | 20.3 | 25.9 | 9.5 |
| 2–3 | 8.2 | 2.9 | 10.1 | 11.1 | 23.8 |
| 4–5 | 4.3 | 0.0 | 2.5 | 0.0 | 38.1 |
| 6–10 | 0.4 | 0.0 | 0.0 | 3.7 | 0.0 |
| >10 | 0.4 | 0.0 | 0.0 | 0.0 | 4.7 |
| Amount of clinical experience diagnosing/treating syphilis | |||||
| None | 34.2 | 64.4 | 11.4 | 7.7 | 4.8 |
| Very inexperienced | 42.0 | 27.9 | 70.9 | 44.4 | 0.0 |
| Somewhat inexperienced | 12.1 | 5.8 | 11.4 | 40.7 | 9.5 |
| Somewhat experienced | 10.0 | 1.0 | 6.3 | 7.4 | 71.4 |
| Very experienced | 1.7 | 1.0 | 0.0 | 0.0 | 14.3 |
| Adequacy of syphilis training | |||||
| Very inadequate | 22.9 | 38.5 | 13.9 | 7.4 | 0.0 |
| Somewhat inadequate | 38.1 | 34.6 | 53.2 | 25.9 | 14.3 |
| Somewhat adequate | 34.2 | 26.0 | 30.4 | 66.7 | 47.6 |
| Very adequate | 4.8 | 1.0 | 2.5 | 0.0 | 38.1 |
| Familiarity with reverse sequence algorithm | |||||
| Never heard of it | 78.4 | 92.3 | 73.4 | 92.3 | 9.5 |
| Somewhat familiar | 13.9 | 6.7 | 22.8 | 3.7 | 28.6 |
| Familiar | 6.1 | 1.0 | 3.8 | 3.7 | 42.9 |
| Very familiar | 1.7 | 0.0 | 0.0 | 0.0 | 19.1 |
| Prior use of reverse sequence algorithm | |||||
| Yes | 12.1 | 1.0 | 15.2 | 3.7 | 66.7 |
| No | 80.5 | 91.4 | 77.2 | 88.9 | 28.6 |
| Unsure | 7.4 | 7.7 | 7.6 | 7.4 | 4.8 |
ID: infectious diseases.
Survey scores by group (ANOVA).
| Sample size ( | Mean ( | ||
|---|---|---|---|
| Epidemiology: five items | |||
| Student | 104 | 1.94 (1.18) | 0.016 |
| Resident or fellow | 79 | 2.16 (1.20) | |
| Attending (other) | 27 | 2.19 (1.27) | |
| Attending (infectious disease) | 21 | 2.86 (1.06) | |
| Total | 231 | 2.13 (1.21) | |
| Transmission: five items | |||
| Student | 104 | 1.96 (1.13) | 0.006 |
| Resident or fellow | 79 | 2.41 (1.30) | |
| Attending (other) | 27 | 2.11 (1.16) | |
| Attending (infectious disease) | 21 | 2.86 (1.20) | |
| Total | 231 | 2.21 (1.22) | |
| Clinical features: five items | |||
| Student | 104 | 1.53 (1.08) | <0.001 |
| Resident or fellow | 79 | 2.25 (0.88) | |
| Attending (other) | 27 | 2.07 (1.33) | |
| Attending (infectious disease) | 21 | 3.43 (0.87) | |
| Total | 231 | 2.01 (1.17) | |
| Diagnosis: five items | |||
| Student | 104 | 1.56 (1.28) | <0.001 |
| Resident or fellow | 79 | 2.23 (1.17) | |
| Attending (other) | 27 | 2.44 (1.12) | |
| Attending (infectious disease) | 21 | 3.52 (1.08) | |
| Total | 231 | 2.07 (1.33) | |
| Treatment: five items | |||
| Student | 104 | 0.69 (0.86) | <0.001 |
| Resident or fellow | 79 | 1.56 (0.97) | |
| Attending (other) | 27 | 1.59 (1.50) | |
| Attending (infectious disease) | 21 | 3.71 (1.38) | |
| Total | 231 | 1.37 (1.34) | |
| Reverse sequence algorithm: three items | |||
| Student | 104 | 0.07 (0.25) | <0.001 |
| Resident or fellow | 79 | 0.37 (0.54) | |
| Attending (other) | 27 | 0.04 (0.19) | |
| Attending (infectious disease) | 21 | 1.81 (1.08) | |
| Total | 231 | 0.32 (0.69) | |
| Knowledge: 25 items | |||
| Student | 104 | 7.68 (3.81) | <0.001 |
| Resident or fellow | 79 | 10.61 (2.69) | |
| Attending (other) | 27 | 10.41 (3.72) | |
| Attending (infectious disease) | 21 | 16.38 (3.60) | |
| Total | 231 | 9.79 (4.23) | |
ANOVA: analysis of variance; σ: standard deviation.
25-item survey performance (percent correct by question).
| Correct response (T/F) | Medical students (%) | Residents/fellows (%) | Non-ID attendings (%) | ID attendings (%) | Total (%) | |
|---|---|---|---|---|---|---|
| Epidemiology | ||||||
| The number of annual cases of primary and secondary syphilis in the United States has remained stable from 2005 to 2015. | F | 75 | 73 | 67 | 95 | 75 |
| Of all primary/secondary cases in the United States, males and females account for approximately the same number per year. | F | 53 | 47 | 70 | 90 | 56 |
| African American/Blacks have the highest rates of syphilis in the United States compared to other racial or ethnic populations. | T | 33 | 42 | 44 | 52 | 39 |
| Gay, bisexual, and other men who have sex with men account for approximately half of all new primary and secondary syphilis cases in the United States each year. | F | 15 | 25 | 19 | 10 | 19 |
| Over half of all new primary and secondary syphilis cases occur among HIV-positive individuals. | F | 18 | 29 | 19 | 38 | 24 |
| Transmission | ||||||
| Syphilis is rarely transmitted by oral sex. | F | 40 | 61 | 52 | 76 | 52 |
| Syphilis is not transmissible via intravenous drug use or contaminated blood. | F | 63 | 61 | 56 | 57 | 61 |
| A developing fetus can be infected transplacentally at any stage of syphilis. | T | 51 | 61 | 33 | 76 | 55 |
| The median time from transmission to onset of symptoms of primary syphilis is 1 week. | F | 33 | 37 | 37 | 38 | 35 |
| A patient with late latent syphilis is not considered to be contagious. | T | 10 | 22 | 33 | 38 | 19 |
| Clinical features | ||||||
| Primary syphilis classically involves a painful ulcer. | F | 53 | 73 | 74 | 81 | 65 |
| A rash is the most common symptom of secondary syphilis. | T | 56 | 77 | 67 | 86 | 67 |
| Syphilis commonly involves the central nervous system during primary and secondary stages of the disease. | T | 16 | 3 | 11 | 19 | 11 |
| Without treatment, half of people infected will develop tertiary disease. | F | 16 | 32 | 30 | 81 | 29 |
| Tabes dorsalis, or posterior column and posterior root spinal cord disease, is the most common manifestation of neurosyphilis. | F | 12 | 41 | 26 | 76 | 29 |
| Diagnosis | ||||||
| Treponemal-specific antibody testing (e.g. FTA, TP-PA) is the classic initial test to diagnose syphilis. | F | 20 | 58 | 63 | 81 | 44 |
| Almost all patients with primary syphilis will have a positive syphilis screening test. | F | 32 | 35 | 33 | 43 | 34 |
| Non-treponemal tests remain elevated through all stages of syphilis (e.g. RPR, VDRL). | F | 27 | 23 | 26 | 52 | 28 |
| Pregnancy can cause a false-positive non-treponemal test (e.g. RPR, VDRL). | T | 30 | 53 | 63 | 76 | 46 |
| The initial screening test for syphilis can involve either a treponemal or non-treponemal test. | T | 47 | 53 | 59 | 100 | 55 |
| Treatment | ||||||
| Secondary syphilis is treated with intramuscular benzathine penicillin G for three doses at weekly intervals. | F | 7 | 14 | 11 | 38 | 13 |
| Late latent syphilis is treated with intravenous penicillin G for 10–14 days. | F | 6 | 27 | 19 | 71 | 20 |
| Ciprofloxacin is a second-line agent for the treatment of syphilis. | F | 19 | 35 | 22 | 81 | 31 |
| Successful treatment of syphilis is measured by a decline in non-treponemal antibody titers. | T | 20 | 25 | 52 | 86 | 32 |
| The Jarisch–Herxheimer reaction following treatment of syphilis is a severe, life-threatening anaphylactic reaction to penicillin. | F | 17 | 54 | 56 | 95 | 42 |
ID: infectious diseases; FTA: fluorescent treponemal antibody; TP-PA: Treponema pallidum particle agglutination; RPR: rapid plasma regain; VDRL: venereal disease research laboratory.